Coombes RC, Chilvers C, Dowsett M, Gazet J-C, Ford HT, Bettelheim R, Gordon C, Smith IE, Zava D, Powles TJ: Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: Progress report. Cancer Res (Suppl) 42: 3415–3419, 1982...
cancer cells can form a huge mass (as in solid tumors) and also migrate to other parts of the body through either blood or lymphatic circulation [1]. In hematologic malignancies, cancer cells will eventually outnumber the normal blood
Amino Acid Availability as a Therapeutic Target for Cancer Therapy Next to forming the building blocks of proteins, amino acids provide many of the structural elements of a cell and are an important source of energy. It is therefore not surprising that cancer cells, although striving to maintain...
MYC Signaling: The oncogene MYC regulates the expression of multiple key metabolic enzymes. Glutamine serves as a source of energy and nitrogen for nucleotide and amino acid biosynthesis [60]. Glutamine metabolism influences signaling pathways such c-MYC, which are implicated in cancer cell growth an...
The near century of progress1in cancer metabolism continues to impact our understanding of oncology. Each decade has yielded new discoveries and engendered additional avenues of research and approaches to therapy. Classically, cancer metabolism has focused on central carbon metabolism, including glycolysis...
The patients selected were on a stable treatment for ≥ 6 weeks and had no planned upcoming changes to their cancer therapy. The patients were screened to meet the requirements needed to participate, such as exclusions for patients with excessive alcohol intake, smoking, use of certain ...
microenvironment (TME). PDAC uses BCKAs secreted by CAFs as substrates for BCAAs synthesis or increases the oxidative metabolic flux of BCKA in a BCKDH-dependent mode.57This study suggests the feasibility of targeting BCAAs metabolism in TME mesenchymal and cancer cells for PDAC therapy (Fig.4...
A polypeptide derivative of p62 having at least one deletion of at least one amino acid between amino acids 145 to 247 of p62, where the derivative inhibits signals transduced by ras.
Moreover, the potential of targeting therapy for LAT1 had been suggested in tumor cell lines by the inhibition of LAT1 using 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) [20, 21]. However, it remains unknown whether LAT1 expression has a clinical and pathological significance ...
Nucleic acids are promising for a variety of therapies, such as cancer therapy and the gene therapy of genetic disorders. The therapeutic efficacy of nucleic acids is reliant on the ability of their efficient delivery to the cytosol of the target cells. Amino lipids have been developed to aid ...